Description
Clopidogrel-TEVA Coated Tablets 75 mg. №30
Ingredients
Active ingredient: Clopidogrel bisulfate. Inactive ingredients: mannitol, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, hydroxypropyl cellulose, and more.
Mechanism of Action
Clopidogrel is a platelet aggregation inhibitor that works by irreversibly binding to the P2Y12 ADP receptor on platelets, preventing platelet activation and aggregation. This antiplatelet effect reduces the risk of thrombotic events in patients with atherosclerosis.
Pharmacological Properties
Clopidogrel-TEVA exhibits pharmacological properties as an antiplatelet agent through its action on platelet receptors, thereby reducing the risk of atherothrombotic events.
Indications for Use
Indicated for: Prevention of atherothrombotic events in patients suffering from acute coronary syndrome, recent myocardial infarction, stroke, or established peripheral arterial disease.
Contraindications
Contraindications: Do not use if hypersensitive to clopidogrel or any component of the formulation, active pathological bleeding, or hepatic impairment.
Side Effects
Clopidogrel-TEVA may cause side effects such as increased risk of bleeding, gastrointestinal disturbances, and allergic reactions. Patients should seek medical attention if any adverse effects occur.
Usage Instructions
Dosage: The usual dose is one tablet daily, with or without food, or as directed by a healthcare professional. The tablet should be swallowed whole with water and not crushed or chewed. Consult a doctor before starting or stopping this medication.
Benefits Compared to Analogues
Clopidogrel-TEVA has shown efficacy in reducing cardiovascular events compared to placebo in clinical trials. Its mechanism of action provides a targeted approach to preventing atherothrombotic events, making it a valuable option for patients at risk.
Suitable Patient Groups
Clopidogrel-TEVA is suitable for adult patients at risk of atherothrombotic events. Special consideration should be given to elderly patients and those with a history of cardiovascular disease to optimize treatment outcomes.
Storage and Shelf Life
Store Clopidogrel-TEVA in a cool, dry place away from direct sunlight. Check the expiration date on the packaging and do not use the product if past the indicated shelf life.
Packaging Description
Clopidogrel-TEVA is available in blister packs containing 30 coated tablets of 75 mg each. The packaging is designed to protect the tablets from environmental factors and maintain their stability until use.
Scientific Evidence
Clinical studies have shown that Clopidogrel-TEVA is effective in reducing the risk of cardiovascular death, myocardial infarction, or stroke compared to placebo. Research published in the New England Journal of Medicine supports the use of clopidogrel for preventing atherothrombotic events.
Additional Information
Precautions: Clopidogrel may increase the risk of bleeding, so caution is advised in patients with a history of gastrointestinal bleeding, recent surgery, or trauma. It is important to inform healthcare providers about all medications being taken to prevent potential drug interactions.
